Biosynergy (BSYN) 10-K 28 Jul 16 2016 FY Annual report Financial data

Document and Entity Information

Document and Entity Information	12 Months Ended
	Apr. 30, 2016USD ($)shares
Document And Entity Information
Entity Registrant Name	BIOSYNERGY INC
Entity Central Index Key	715,812
Document Type	10-K
Document Period End Date	Apr. 30, 2016
Amendment Flag	false
Current Fiscal Year End Date	--04-30
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float | $	$ 8,029,291
Entity Common Stock, Shares Outstanding | shares	14,935,511
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2,016

Balance Sheets

Balance Sheets - USD ($)	Apr. 30, 2016	Apr. 30, 2015
Current Assets
Cash	$ 1,091,649	$ 975,777
Accounts receivable - Trade (Net of allowance for doubtful accounts of $500 in both 2016 and 2015)	192,051	162,988
Inventories	108,960	155,394
Prepaid expenses	25,958	26,524
Total current assets	1,418,618	1,320,683
Equipment and Leasehold Improvements
Equipment	198,640	197,517
Leasehold improvements	20,022	20,022
[PropertyPlantAndEquipmentGross]	218,662	217,539
Less accumulated depreciation and amortization	203,276	195,278
Total equipment and leasehold improvements	15,386	22,261
Other Assets
Patents less accumulated amortization	79,057	87,742
Patents pending	60,788	43,950
Deposits	5,937	5,937
Total other assets	145,782	137,629
[Assets]	1,579,786	1,480,573
Deferred income taxes	32,110	32,110
Current Liabilities
Accounts payable	4,595	15,514
Accrued compensation and payroll taxes	39,206	39,827
Other accrued expenses	3,545	2,924
Accrued vacation	21,835	17,977
Total current liabilities	69,181	76,242
Stockholders Equity
Common stock - No par value; 20,000,000 shares authorized; 14,935,511 shares issued as of both April 30, 2015 and 2014	660,988	660,988
Receivable from affiliate	(19,699)	(19,699)
Retained earnings	837,206	730,932
Total stockholders equity	1,478,495	1,372,221
[LiabilitiesAndStockholdersEquity]	$ 1,579,786	$ 1,480,573

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - USD ($)	Apr. 30, 2016	Apr. 30, 2015
Statement of Financial Position [Abstract]
Net of allowance for doubtful accounts	$ 500	$ 500
Common stock, no par value	20,000,000	20,000,000
Authorized shares issued and outstanding	14,935,511	14,935,511

Statements of Operations

Statements of Operations - USD ($)	12 Months Ended
	Apr. 30, 2016	Apr. 30, 2015
Income Statement [Abstract]
Net sales	$ 1,337,952	$ 1,360,768
Cost of sales	414,794	428,360
Gross profit	923,158	932,408
Operating Expenses
Marketing	199,183	198,884
General and administrative	421,373	428,322
Research and development	157,444	149,218
Total operating expenses	778,000	776,424
Income from operations	145,158	155,984
Other Income
Interest income	411	457
Other income	1,920	1,920
Total other income	2,331	2,377
Net income before income taxes	147,489	158,361
Provision for income taxes	41,215	44,772
Net income	$ 106,274	$ 113,589
Net income per common share-basic and diluted	$ .007	$ 0.008
Weighted-average common stock outstanding-basic and diluted	14,935,511	14,935,511

Statements of Cash Flows

Statements of Cash Flows - USD ($)	12 Months Ended
	Apr. 30, 2016	Apr. 30, 2015
Cash Flows from Operating Activities
Net income	$ 106,274	$ 113,589
Adjustments to reconcile net income to net cash provided by operating activities
Depreciation and amortization	16,683	18,517
Deferred income taxes		8,288
Abandonment of patents pending		9,862
Changes in assets and liabilities
Accounts receivable	(29,063)	27,761
Inventories, prepaid expenses and other	47,000	(30,346)
Accounts payable and accrued expenses	(7,061)	(667)
Total adjustments	27,559	33,415
Net cash provided by operating activities	133,833	147,004
Cash Flows from Investing Activities
Purchase of equipment	(1,123)	(1,616)
Patents and patents pending	(16,838)	(34,139)
Net cash (used in) provided by investing activities	(17,961)	(35,755)
Increase in cash	115,872	111,249
Cash, beginning of year	975,777	864,528
Cash, end of year	1,091,649	975,777
Supplemental disclosure of cash flow information
Income taxes paid	37,800	32,974
Interest paid

Shareholders Equity

Shareholders Equity - USD ($)	Common Stock	Retained Earnings	Receivable from Affiliate Member	Total
Beginning Balance at Apr. 30, 2014		$ 617,343	$ (19,699)	$ 1,258,632
Common Stock Outstanding at Apr. 30, 2014	14,935,511
Common Stock Value at Apr. 30, 2015	$ 660,988
Net Income		113,589		113,589
Ending Balance at Apr. 30, 2015		730,932	(19,699)	$ 1,372,221
Common Stock Outstanding at Apr. 30, 2015	14,935,511			14,935,511
Common Stock Value at Apr. 30, 2016	$ 660,988
Net Income		106,274		$ 106,274
Ending Balance at Apr. 30, 2016		$ 837,206	$ (19,699)	$ 1,478,495

Company Organization and Descri

Company Organization and Description	12 Months Ended
	Apr. 30, 2016
Notes to Financial Statements
Company Organization and Description	Biosynergy, Inc. (the Company) was incorporated under the laws of the state of Illinois on February 9, 1976. The Company is primarily engaged in the development and marketing of medical, consumer and industrial thermometric and thermographic products that utilize cholesteric liquid crystals. The Company’s primary product, the HemoTemp R

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Apr. 30, 2016
Notes to Financial Statements
Summary of Significant Accounting Policies	Cash The Company maintains all of its cash in bank deposit accounts, which at times may exceed federally insured limits. No losses have been experienced on such accounts. All cash is held with Bank of America, N.A., JPMorgan Chase Bank, N.A., and BMO Harris, N.A. Receivables Receivables are carried at original invoice less estimates made for doubtful receivables. Management determines the allowance for doubtful accounts by reviewing and identifying troubled accounts on a periodic basis by using historical experience applied to an aging of accounts. A receivable is considered to be past due if any portion of the receivable balance is outstanding for more than 30 days. Receivables are written off when deemed uncollectible. Recoveries of receivables previously written off are recorded when received. Inventories Inventories are valued using the FIFO (first-in, first-out) method at the lower of cost or market. Depreciation and Amortization Equipment and leasehold improvements are stated at cost. Depreciation is computed primarily using the straight-line method over the estimated useful lives of the respective assets. Repairs and maintenance are charged to expense as incurred. Renewals and betterments, which significantly extend the useful lives of existing equipment, are capitalized. Significant leasehold improvements are capitalized and amortized over 10 years or the term of the lease, if shorter. Equipment is depreciated over three to 10 years. Prepaid Expenses Certain expenses, primarily insurance and income taxes, have been prepaid and will be used within one year. Revenue Recognition The Company recognizes net sales revenue upon the shipment of products to customers. Shipping and Handling Shipping and handling fees billed to customer, if any, are netted against the related costs which are included in cost of sales. The net cost is not material. Income Taxes Income taxes are provided for the tax effects of transactions reported in the financial statements and consist of taxes currently due and deferred taxes related primarily to differences in the methods of accounting for patents, inventories, certain accrued expenses and bad debt expenses for financial and income tax reporting purposes. The deferred income taxes represent the future tax consequences of those differences, which will be taxable in the future. See Note 4 for additional information regarding income taxes. The Company files tax returns in the U.S. federal jurisdiction and with the state of Illinois. Various tax years remain open to examinations, generally for three years after filing, although there are currently no ongoing tax examinations. Management’s policy is to recognize interest and penalties related to uncertain tax positions in income tax expense. Management does not believe that there are any uncertain tax positions as of April 30, 2016. Research and Development and Patents Research and development expenditures are charged to operations as incurred. The costs of obtaining patents, primarily legal fees, are capitalized and, once obtained, are amortized over the life of the respective patent using the straight-line method. Patents relate to products that have been developed and are being marketed by the Company. Patents pending relate to products under development. The Company wrote-off $9,862 for the year ended April 30, 2015 for abandoned patents. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Income Per Common Share Income per common share is computed by dividing net income by the weighted-average number of common shares outstanding during the period. Basic and diluted net income per common share is the same for the years ended April 30, 2016 and 2015 as there are no common stock equivalents. Fair Value of Financial Instruments The Company evaluates its financial instruments based on current market interest rates relative to stated interest rates, length to maturity and the existence of readily determinable market prices. Based on the Company’s analysis, the fair value of financial instruments recorded on the balance sheets as of April 30, 2016 and 2015, approximates their carrying value. Recent Accounting Pronouncements The FASB issues ASUs to amend the authoritative literature in Accounting Standards Certification (ASC). There have been a number of ASUs to date that amend the original text of ASCs. Except for the ASUs listed below, those issued to date either (i) provide supplemental guidance, (ii) are technical corrections, (iii) are not applicable to the Company or (iv) are not expected to have a significant impact on the Company. On February 25, 2016, the FASB issued Topic 842, its highly-anticipated leasing standard for both lessees and lessors. Under its core principle, a lessee will recognize lease assets and liabilities on the balance sheet for all arrangements with terms longer than 12 months. Lessor accounting remains largely consistent with existing U.S. GAAP. The amendments are effective for public companies for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. At inception, a lessee must classify all leases as either finance or operating. The Company intends to adopt Topic 842 upon extension of the current lease for its facilities in Elk Grove Village or upon entering into a new lease agreement for alternative facilities on or about May 1, 2018. The Company is investigating the effect of adoption of Topic 842 on its results of operations and financial condition. However, it is not anticipated that adoption of Topic 842 will have a material impact on the results of operations or financial condition of the Company. In May 2014, the Financial Accounting Standard Board (FASB) issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606) (“ASU 2014-09”). ASU 2014-09 supersedes the revenue recognition requirements in ASC Topic 605, Revenue Recognition, and most industry-specific guidance. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This guidance is effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period, under either full or modified retrospective adoption. Early application is not permitted. The Company plans to adopt ASU 2014-09 beginning May 1, 2017, and management is currently assessing the potential effects of these changes to the Company’s consolidated financial statements.

Inventories

Inventories	12 Months Ended
	Apr. 30, 2016
Notes to Financial Statements
Inventories	2016 2015 Raw Materials $ 83,231 $ 115,071 Work-in-process 16,303 28,384 Finished goods 9,426 11,939 $ 108,960 $ 155,394

Income Taxes

Income Taxes	12 Months Ended
	Apr. 30, 2016
Income Tax Disclosure [Abstract]
Income Taxes	The components of the deferred income tax (assets) and liabilities as of April 30, 2016 and 2015 are as follows: 2016 2015 Total deferred tax liabilities Patents $ 38,330 $ 34,875 Prepaid and other $ 7,012 6,428 45,342 41,303 Total deferred tax assets Accrued vacation pay (7,084 ) (5,772 ) Equipment and leaseholds (4,488 ) (1,805 ) Other (1,660 ) (1,616 ) (13,232 ) (9,193 ) Net deferred income tax liabilities $ 32,110 $ 32,110 Deferred income tax liabilities result primarily from prepaid expenses and capitalized legal costs associated with patents that are deducted immediately for income tax purposes. Deferred income tax assets result primarily from accrued vacation pay, which is not deducted for tax purposes unless it is paid within 2½ months of each year-end, other expenses, which are not deductible for tax purposes until paid and from differences between depreciation expense for book and tax purposes. The provision for income taxes consists of the following components: 2016 2015 Current Federal $ 30,695 $ 25,836 State 10,520 10,648 41,215 36,484 Deferred — 8,288 $ 41,215 $ 44,772 The differences between the U.S. federal statutory tax rate and the Company’s effective tax rate are as follows: Year Ended April 30, 2016 2015 U.S. federal statutory tax rate 34.0 % 34.0 % State income tax expense, net of 6.0 6.0 Effect of graduated federal tax rates and other (12.06 ) (11.7 ) Effective tax rate 27.94 % 28.3 %

Related Party Transactions

Related Party Transactions	12 Months Ended
	Apr. 30, 2016
Notes to Financial Statements
Related Party Transactions	The Company and its affiliates are related through common stock ownership as follows as of April 30, 2016: Stock of Affiliates Biosynergy, Inc. F.K. Suzuki International, Inc. Medlab, Inc. F.K. Suzuki International, Inc. 30.0 % — % 100 % Fred K. Suzuki, Officer 4.1 30.0 — Jeanne S. Addis, as Trustee — 28.1 — James F. Schembri, Director 8.6 — — Mary K. Friske, Officer 0.3 0.7 — Laurence C. Mead, Officer 0.4 10.0 — Beverly R. Suzuki, Officer 2.7 — — Lauane C. Addis, Officer — — — As of April 30, 2016 and 2015, $19,699 was due from F.K. Suzuki International, Inc. (FKSI). This balance is resulted from an allocation of common expenses charged to FKSI offset by advances received from time to time. No interest income is received or accrued by the Company. The financial condition of FKSI is such that it will likely be unable to repay the Company without liquidating a portion of its assets, including a portion of its ownership in the Company. As a result, the total receivable balance of $19,699 was reclassified as a contra equity account. A board member provides a variety of legal services to the Company in his capacity as a partner in a law firm. Fees for such legal services were $17,984 and $29,165 for the years ended April 30, 2016 and 2015, respectively.

Lease Commitments

Lease Commitments	12 Months Ended
	Apr. 30, 2016
Leases [Abstract]
Lease Commitments	In January 2015, the Company entered into a three-year lease agreement for its current facilities, which expires on April 30, 2018. The base rent under the lease escalates over the life of the lease. However, rent expense is recorded on a straight-line basis as required by accounting principles generally accepted in the United States of America. As of April 30, 2016, the Company’s approximate total future minimum lease payments are as follows: Year Ending April 30: 2017 $ 86,675 2018 89,275 Also included in the lease agreement are escalation clauses for the lessor’s increases in property taxes and other operating expenses. Rent expense was $86,700 for fiscal year ended April 30, 2016 and $70,200 for fiscal year ended April 30, 2015.

Customer Concentrations

Customer Concentrations	12 Months Ended
	Apr. 30, 2016
Notes to Financial Statements
Customer Concentrations	Shipments to one customer amounted to approximately 28.3% and 29.6% of sales in fiscal years 2016 and 2015, respectively. As of April 30, 2016 and 2015, there were outstanding accounts receivable from this customer of approximately $73,031 and $76,475, respectively. Shipments to another customer accounted for 37.5% and 33.2% of sales in fiscal years 2016 and 2015, respectively. As of April 30, 2016 and 2015, there were outstanding accounts receivable from this customer of approximately $60,497 and $43,415, respectively. The Company had export sales of $49,240 during the last fiscal year, and export sales of $140,300 during the fiscal year ending in 2015. The Company also believes that some of its medical devices were sold to distributors within the United States who resold the devices in foreign markets. However, the Company does not have any information regarding such sales, and such sales are not considered to be material. The Company does not rely on any foreign operations other than its dealers and marketing representatives in their respective marketing areas. See "Marketing and Distribution." Foreign sales are contingent upon, among other factors, foreign trade regulations, value of the United States Dollar and, where required, government approval of the Company's products including CE Marketing requirements. The Company is exposed to risks generally attendant to foreign operations, including but not limited to, trade restrictions, tariffs, embargos, foreign war and unrest and competition from foreign and domestic producers. Management believes the partial or total loss of foreign operations would not have a material impact on the Company’s financial condition or results of operations.

Employee Benefit Plan

Employee Benefit Plan	12 Months Ended
	Apr. 30, 2016
Notes to Financial Statements
Employee Benefit Plan	The Company sponsors a 401(k) plan for all full-time employees. Under the plan, a participant may elect to defer compensation (up to allowable limits). The Company's discretionary contributions for the years ended April 30, 2016 and 2015 were $25,818 and $25,785, respectively.

Summary of Significant Accoun15

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Apr. 30, 2016
Notes to Financial Statements
Cash	Cash The Company maintains all of its cash in bank deposit accounts, which at times may exceed federally insured limits. No losses have been experienced on such accounts. All cash is held with Bank of America, N.A., JPMorgan Chase Bank, N.A., and BMO Harris, N.A.
Receivables	Receivables Receivables are carried at original invoice less estimates made for doubtful receivables. Management determines the allowance for doubtful accounts by reviewing and identifying troubled accounts on a periodic basis by using historical experience applied to an aging of accounts. A receivable is considered to be past due if any portion of the receivable balance is outstanding for more than 30 days. Receivables are written off when deemed uncollectible. Recoveries of receivables previously written off are recorded when received.
Inventories	Inventories Inventories are valued at the lower of cost or market using the FIFO (first-in, first-out) method.
Depreciation and Amortization	Depreciation and Amortization Equipment and leasehold improvements are stated at cost. Depreciation is computed primarily using the straight-line method over the estimated useful lives of the respective assets. Repairs and maintenance are charged to expense as incurred. Renewals and betterments, which significantly extend the useful lives of existing equipment, are capitalized. Significant leasehold improvements are capitalized and amortized over 10 years or the term of the lease, if shorter. Equipment is depreciated over three to 10 years.
Prepaid Expenses	Prepaid Expenses Certain expenses, primarily insurance and income taxes, have been prepaid and will be used within one year.
Revenue Recognition	Revenue Recognition The Company recognizes net sales revenue upon the shipment of products to customers.
Shipping and Handling	Shipping and Handling Shipping and handling fees billed to customer, if any, are netted against the related costs which are included in cost of sales. The net cost is not material.
Income Taxes	Income Taxes Income taxes are provided for the tax effects of transactions reported in the financial statements and consist of taxes currently due and deferred taxes related primarily to differences in the methods of accounting for patents, inventories, certain accrued expenses and bad debt expenses for financial and income tax reporting purposes. The deferred income taxes represent the future tax consequences of those differences, which will be taxable in the future. See Note 4 for additional information regarding income taxes. The Company files tax returns in the U.S. federal jurisdiction and with the state of Illinois. Various tax years remain open to examinations, generally for three years after filing, although there are currently no ongoing tax examinations. Management’s policy is to recognize interest and penalties related to uncertain tax positions in income tax expense. Management does not believe that there are any uncertain tax positions as of April 30, 2015.
Research and Development and Patents	Research and Development and Patents Research and development expenditures are charged to operations as incurred. The costs of obtaining patents, primarily legal fees, are capitalized and, once obtained, are amortized over the life of the respective patent using the straight-line method. Patents relate to products that have been developed and are being marketed by the Company. Patents pending relate to products under development. The Company wrote-off $9,862 and $98,100 for the years ended April 30, 2015 and 2014, respectively, for abandoned patents.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Income Per Common Share	Income Per Common Share Income per common share is computed by dividing net income by the weighted-average number of common shares outstanding during the period. Basic and diluted net income per common share is the same for the years ended April 30, 2015 and 2014 as there are no common stock equivalents.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company evaluates its financial instruments based on current market interest rates relative to stated interest rates, length to maturity and the existence of readily determinable market prices. Based on the Company’s analysis, the fair value of financial instruments recorded on the balance sheets as of April 30, 2015 and 2014, approximates their carrying value.
Recent Accounting Pronouncements	Recent Accounting Pronouncements The FASB issues ASUs to amend the authoritative literature in Accounting Standards Certification (ASC). There have been a number of ASUs to date that amend the original text of ASCs. Except for the ASUs listed above, those issued to date either (i) provide supplemental guidance, (ii) are technical corrections, (iii) are not applicable to the Company or (iv) are not expected to have a significant impact on the Company.

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Apr. 30, 2016
Notes to Financial Statements
Inventories	2016 2015 Raw Materials $ 83,231 $ 115,071 Work-in-process 16,303 28,384 Finished goods 9,426 11,939 $ 108,960 $ 155,394

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Apr. 30, 2016
Income Tax Disclosure [Abstract]
Deferred Income Tax Liabilities	2016 2015 Total deferred tax liabilities Patents $ 38,330 $ 34,875 Prepaid and other $ 7,012 6,428 45,342 41,303 Total deferred tax assets Accrued vacation pay (7,084 ) (5,772 ) Equipment and leaseholds (4,488 ) (1,805 ) Other (1,660 ) (1,616 ) (13,232 ) (9,193 ) Net deferred income tax liabilities $ 32,110 $ 32,110
Components of Income Taxes	2016 2015 Current Federal $ 30,695 $ 25,836 State 10,520 10,648 41,215 36,484 Deferred — 8,288 $ 41,215 $ 44,772
Effective Tax Rate	Year Ended April 30, 2016 2015 U.S. federal statutory tax rate 34.0 % 34.0 % State income tax expense, net of 6.0 6.0 Effect of graduated federal tax rates and other (12.06 ) (11.7 ) Effective tax rate 27.94 % 28.3 %

Related Party Transactions (Tab

Related Party Transactions (Tables)	12 Months Ended
	Apr. 30, 2016
Notes to Financial Statements
Stock of Affiliates	Stock of Affiliates Biosynergy, Inc. F.K. Suzuki International, Inc. Medlab, Inc. F.K. Suzuki International, Inc. 30.0 % — % 100 % Fred K. Suzuki, Officer 4.1 30.0 — Jeanne S. Addis, as Trustee — 28.1 — James F. Schembri, Director 8.6 — — Mary K. Friske, Officer 0.3 0.7 — Laurence C. Mead, Officer 0.4 10.0 — Beverly R. Suzuki, Officer 2.7 — — Lauane C. Addis, Officer — — —

Lease Commitments (Tables)

Lease Commitments (Tables)	12 Months Ended
	Apr. 30, 2016
Notes to Financial Statements
Future Minimum Lease Payments	Year Ending April 30: 2017 $ 86,675 2018 89,275

Research and Development and Pa

Research and Development and Patents (Details) - USD ($)	12 Months Ended
	Apr. 30, 2016	Apr. 30, 2015
Research and Development Expense [Abstract]
Abandonment of Patents		$ 9,862

Inventories - Inventories (Deta

Inventories - Inventories (Details) - USD ($)	Apr. 30, 2016	Apr. 30, 2015
Notes to Financial Statements
Raw Materials	$ 83,231	$ 115,071
Work-in-process	16,303	28,384
Finished goods	9,426	11,939
[InventoryGross]	$ 108,960	$ 155,394

Income Taxes - Deferred Income

Income Taxes - Deferred Income Tax Liabilities (Details) - USD ($)	Apr. 30, 2016	Apr. 30, 2015
Income Tax Disclosure [Abstract]
Patents	$ 38,330	$ 34,875
Prepaid and other	7,012	6,428
[DeferredTaxLiabilities]	45,342	41,303
Total deferred tax assets
Accrued vacation pay	(7,084)	(5,772)
Equipment and leaseholds	(4,488)	(1,805)
Other	(1,660)	(1,616)
[DeferredTaxAssetsNet]	(13,232)	(9,193)
Net deferred income tax liabilities	$ 32,110	$ 32,110

Income Taxes - Components of In

Income Taxes - Components of Income Taxes (Details) - USD ($)	12 Months Ended
	Apr. 30, 2016	Apr. 30, 2015
Income Tax Disclosure [Abstract]
Federal	$ 30,695	$ 25,836
State	10,520	10,648
[AccruedIncomeTaxes]	41,215	36,484
Deferred		8,288
Total Income Tax Expense	$ 41,215	$ 44,772

Income Taxes (Details Narrative

Income Taxes (Details Narrative)	12 Months Ended
	Apr. 30, 2016	Apr. 30, 2015
Income Tax Disclosure [Abstract]
U.S. federal statutory tax rate	34.00%	34.00%
State income tax expense, net of federal tax benefit	6.00%	6.00%
Effect of graduated federal tax rates and other	(12.06%)	(11.70%)
[us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate]	27.94%	28.30%

Related Party Transactions (Nar

Related Party Transactions (Narrative Details) - USD ($)	12 Months Ended
	Apr. 30, 2016	Apr. 30, 2015
Notes to Financial Statements
Receivable from affiliate	$ 19,699	$ 19,699
Legal Fees	$ 17,984	$ 29,165

Lease Commitments (Details Narr

Lease Commitments (Details Narrative) - USD ($)	12 Months Ended
	Apr. 30, 2018	Apr. 30, 2017	Apr. 30, 2016	Apr. 30, 2015
Leases [Abstract]
Rent Expense	$ 89,275	$ 86,675	$ 86,700	$ 70,200

Lease Commitments - Future Mini

Lease Commitments - Future Minimum Lease Expense (Details) - USD ($)	12 Months Ended
	Apr. 30, 2018	Apr. 30, 2017	Apr. 30, 2016	Apr. 30, 2015
Leases [Abstract]
Future Minimum Lease Expense	$ 89,275	$ 86,675	$ 86,700	$ 70,200

Major Customers (Details)

Major Customers (Details) - USD ($)	12 Months Ended
	Apr. 30, 2016	Apr. 30, 2015
Exports	$ 49,240	$ 140,300
Customer One
Accounts Receivable	$ 73,031	$ 76,475
Sales	28.30%	29.60%
Customer Two
Accounts Receivable	$ 60,497	$ 43,415
Sales	37.50%	33.20%

Employee Benefit Plan (Narrativ

Employee Benefit Plan (Narrative Details) - USD ($)	12 Months Ended
	Apr. 30, 2016	Apr. 30, 2015
Notes to Financial Statements
401(k) Contributions	$ 25,818	$ 25,785